Evidence map›Paper›PMID 42721252›Full record

ArticleScience (New York, N.Y.)2026

Lean adipocyte oxylipin signaling restrains breast cancer through ferroptosis.

Meghan C Curtin, Abigail E Jackson, Mark D Lee, Elisabeth A Brown, J Alan Maschek, David H Lum, James E Cox, Alana L Welm, Keren I Hilgendorf

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Meghan C CurtinDepartment of Biochemistry, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-1415-0726
Abigail E JacksonDepartment of Biochemistry, University of Utah, Salt Lake City, UT, USA.ORCID 0009-0004-9842-5695
Mark D LeeDepartment of Biochemistry, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-9083-2323
Elisabeth A BrownDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-1924-7946
J Alan MaschekDepartment of Biochemistry, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-3217-2299
David H LumHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-0159-8724
James E CoxDepartment of Biochemistry, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-5977-2350
Alana L WelmDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-1412-1351
Keren I HilgendorfDepartment of Biochemistry, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-8377-8384

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Tolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Alana L. Welm · 2017 to 2026
$13.5M
Ciliary signaling mechanisms regulating white adipose tissue expansionR01DK133455 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Keren Hilgendorf · 2022 to 2026
$1.9M
Huntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling (Cancer GEMS) Training ProgramT32CA265782 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Donald E Ayer, Sheri L Holmen · 2023 to 2026
$1.0M
Agilent 6550 QTOF system for U of UtahS10OD016232 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2013 to 2013
$578k
Q-ToF Mass Spectrometer for the University of Utah MS and Proteomics CoreS10OD018210 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2015 to 2015
$530k
Agilent 7200 GC/Q-TOF for the University of UtahS10OD021505 · OD · UNIVERSITY OF UTAH · PI COX, JAMES ERIC · 2016 to 2016
$401k
Investigation of the preadipocyte primary cilia signalosomeF31DK139738 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Mark David Lee · 2024 to 2026
$136k
NCI NIH HHS P30 CA042014NCI NIH HHS T32 CA265782NCI NIH HHS U54 CA224076NIDDK NIH HHS F31 DK139738NIDDK NIH HHS R01 DK133455NIH HHS S10 OD016232NIH HHS S10 OD018210NIH HHS S10 OD021505
6 · The paper itself

Abstract

Obesity increases breast cancer risk and tumor aggressiveness, yet the mechanisms underlying this association remain unclear. In this work, we identify a tumor-suppressive lipid signaling pathway in which mammary adipocytes secrete the oxylipin 9S-hydroxyoctadecadienoic acid (9S-HODE). 9S-HODE induces ferroptosis in breast cancer cells by disrupting iron homeostasis. Adipocytes in obese mammary tissue produce less 9S-HODE, and tumors in obese mice exhibit reduced ferroptosis. Accordingly, ferroptosis inhibition accelerates tumor growth in lean mice, and restoring 9S-HODE suppresses tumor growth in obese mice. In humans, mammary 9S-HODE content is inversely correlated with body mass index, and 9S-HODE inhibits patient-derived breast cancer organoid growth. These findings identify the loss of adipocyte-derived 9S-HODE as a mechanism by which obesity promotes breast cancer and suggest that the restoration of ferroptosis-inducing lipid signaling may be a therapeutic strategy.

Indexed as

AdipocytesBreast NeoplasmsFatty Acids, UnsaturatedFerroptosisLinoleic AcidsObesityOxylipinsAnimalsCell Line, TumorFemaleHumansIronMiceMice, Inbred C57BLSignal Transduction9-hydroxyoctadecadienoic acidFatty Acids, UnsaturatedIronLinoleic AcidsOxylipins

Identifiers

PMID42721252
PMCPMC13573833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.